Central nervous system relapse of acute promyelocytic leukemia treated by oral Venetoclax with Azacitidine achieved complete remission

Ann Hematol. 2022 Aug;101(8):1865-1867. doi: 10.1007/s00277-022-04823-w. Epub 2022 Mar 26.

Authors

Yanling Li¹, Haibin Dai², Dandan Yao², Xinyu Gao², Yanming Xue², Wei Wang³

Affiliations

¹ Harbin Medical University, Harbin, China.
² Department of Hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
³ Department of Hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. Wangweihrb2021@163.com.

PMID: 35347396
DOI: 10.1007/s00277-022-04823-w

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Azacitidine / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic
Central Nervous System
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Promyelocytic, Acute* / drug therapy
Recurrence
Remission Induction
Sulfonamides

Substances

Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
Azacitidine
venetoclax

Grants and funding